Neogen Chemicals Ltd (BOM:542665) reports a 22% revenue increase and a 71% EBITDA boost, while navigating pricing pressures and strategic shifts.

Life sciences company Neogen (NASDAQ:NEOG) in Q4 CY2024, but sales were flat year on year at $231.3 million. Its non-GAAP ...

Neogen widened its loss in the second quarter as a charge tied to a business it acquired from materials company 3M weighed on the bottom line. The food-safety and animal-safety products widened ...

Neogen, which belongs to the Zacks Medical - Products industry, posted revenues of $231.26 million for the quarter ended November 2024, surpassing the Zacks Consensus Estimate by 2.16%.